Cells (Jul 2024)

Altered Monocyte and Lymphocyte Phenotypes Associated with Pathogenesis and Clinical Efficacy of Progestogen Therapy for Peritoneal Endometriosis in Adolescents

  • Elena P. Khashchenko,
  • Lyubov V. Krechetova,
  • Polina A. Vishnyakova,
  • Timur Kh. Fatkhudinov,
  • Eugeniya V. Inviyaeva,
  • Valentina V. Vtorushina,
  • Elena A. Gantsova,
  • Viktoriia V. Kiseleva,
  • Anastasiya S. Poltavets,
  • Andrey V. Elchaninov,
  • Elena V. Uvarova,
  • Vladimir D. Chuprynin,
  • Gennady T. Sukhikh

DOI
https://doi.org/10.3390/cells13141187
Journal volume & issue
Vol. 13, no. 14
p. 1187

Abstract

Read online

Background: Immunological imbalances characteristic of endometriosis may develop as early as the primary manifestations of the disease in adolescence. Objective: To evaluate subpopulation dynamics of monocytes and lymphocytes in peripheral blood and peritoneal fluid of adolescents with peritoneal endometriosis at diagnosis and after 1-year progestogen therapy. Methods: This study included 70 girls, 13–17 years old, diagnosed laparoscopically with peritoneal endometriosis (n = 50, main group) or paramesonephric cysts (n = 20, comparison group). Phenotypes of monocytes and lymphocytes of the blood and macrophages of the peritoneal fluid were analyzed by flow cytometry at diagnosis and during progestogen therapy. Results: Differential blood counts of CD16+ (p + (p = 0.017) monocytes were identified as independent risk factors for peritoneal endometriosis in adolescents. During the treatment, cytotoxic lymphocytes CD56dimCD16bright (p = 0.049) and CD206+ monocytes (p p = 0.017). The CD56dimCD16bright blood counts before (p p = 0.006), as well as CD206+ blood counts during the treatment (p = 0.038), were associated with the efficacy of pain relief after 1-year progestogen therapy. Conclusions: Adolescents with peritoneal endometriosis have altered counts of pro- and anti-inflammatory monocytes and lymphocytes both before and after 1-year progestogen therapy, correlating with treatment efficacy and justifying long-term hormonal therapy.

Keywords